Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease, PMID: 28304224
Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia, PMID: 32865373
Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor, PMID: 29353350
Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia, PMID: 31648705
Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS), PMID: 31479722
Evolocumab: Considerations for the Management of Hyperlipidemia, PMID: 29511875
Effect of Evolocumab on Coronary Plaque Composition, PMID: 30336824
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial, PMID: 28927706
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial, PMID: 27846344
Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study, PMID: 32234462
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial, PMID: 28859947
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia, PMID: 24678979
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), PMID: 29133605
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events, PMID: 25773607
A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab, PMID: 27231792
Evolocumab, PMID: 29999810
Long-Term Evolocumab in Patients With Familial Hypercholesterolemia, PMID: 32057369
Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization, PMID: 33197560
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial, PMID: 31116355
Cognition After Lowering LDL-Cholesterol With Evolocumab, PMID: 32381158
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial, PMID: 27039291
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial, PMID: 31196453
Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia, PMID: 28971955
Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period: A Placebo-Controlled, Randomized Trial, PMID: 32718248
Evolocumab in Children with Heterozygous Familial Hypercholesterolemia, PMID: 32997915
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial, PMID: 24825642
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER, PMID: 29626068
Cognitive Function in a Randomized Trial of Evolocumab, PMID: 28813214
Evolocumab: A Review in Hyperlipidemia, PMID: 26643308
Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial, PMID: 32347885
Evolocumab reduces LDL-cholesterol levels in FH, PMID: 32913308
Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome, PMID: 31495548
Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics, PMID: 31841795
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis, PMID: 32312223
Effects of Evolocumab on Cardiovascular Events, PMID: 28925859
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial, PMID: 31707849
Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial, PMID: 32785614
Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial, PMID: 26946077
Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia, PMID: 31973581
Profile of evolocumab and its cost-effectiveness in patients with high cardiovascular risk: literature review, PMID: 30014724
Evolocumab: First Global Approval, PMID: 26323342
Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia, PMID: 30464416
The efficacy of evolocumab in the management of hyperlipidemia: a systematic review, PMID: 28488460
Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients, PMID: 31686828
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial, PMID: 25282520
A safety evaluation of evolocumab, PMID: 28988500
Cost-effectiveness of Evolocumab, PMID: 30509368
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial, PMID: 25282519
[Evolocumab and PROFICIO Project: Initial Results], PMID: 26652783
Profile of evolocumab and its potential in the treatment of hyperlipidemia, PMID: 26109850
Alirocumab versus Evolocumab on Cardiovascular Outcomes: A Systematic Review and Meta-analysis., PMID:40511660
Statins Versus Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Primary Cardiovascular Prevention in High-Risk Patients: A Systematic Review., PMID:40486443
Biomimetic nanocomplexes loading with evolocumab and curcumin for synergistic anti-atherosclerosis therapy in ApoE-/- mice., PMID:40462197
Association between novel agents targeting proprotein convertase subtilisin/kexin type 9 and cancer incidence., PMID:40447742
Impact of In-Hospital PCSK9 Inhibition on Myocardial Inflammation After Myocardial Infarction: A Randomized Clinical Trial., PMID:40439630
Impact of evolocumab on plaque phenotypic changes in patients with acute coronary syndrome and elevated lipoprotein(a) levels: a HUYGENS secondary analysis., PMID:40424182
Design of the "EAST" strategy in patients with symptomatic intracranial atherosclerotic stenosis., PMID:40417113
Efficacy and safety of evolocumab in statin-treated patients with cardiovascular risk factors: a systematic review and meta-analysis., PMID:40402652
A dual-targeting bio-liposomes nanodrug repair endothelial cell dysfunction and restore macrophage cholesterol flow homeostasis to treat early atherosclerosis., PMID:40394654
Clinical benefits of evolocumab in diabetic patients with STEMI undergoing PCI: a retrospective study., PMID:40385035
Improvement of retinal microvascular function after initiation of lipid-lowering therapy with PCSK9 inhibitors - An observational study., PMID:40360377
Comparative Efficacy of Non-Statin Lipid-Lowering Therapies in Patients With Hypercholesterolemia at Increased Cardiovascular Risk: An Updated Network Meta-Analysis., PMID:40358978
Evolocumab Versus Statins and Placebo in Patients With Cardiovascular Disease and Comorbidities: A Systematic Review and Meta-Analysis., PMID:40351996
Effects of Alirocumab and Evolocumab on Cardiovascular Mortality and LDL-C: Stratified According to the Baseline LDL-C Levels., PMID:40351695
[Huotan Jiedu Tongluo Decoction inhibits ferroptosis by regulating Nrf2/GPX4 pathway to ameliorate atherosclerotic lesions in ApoE~(-/-) mice]., PMID:40350883
RNA interference versus antibody-based PCSK9 inhibition for the prevention of cardiovascular disease: A drug-target Mendelian randomization study., PMID:40347490
Proprotein convertase subtilisin/kexin type 9 contributes to cisplatin-induced acute kidney injury by interacting with cyclase-associated protein 1 to promote megalin lysosomal degradation., PMID:40339661
Effectiveness of alirocumab and evolocumab (PCSK9i) for the treatment of hypercholesterolemia., PMID:40339450
Expanding Our Understanding of Plaque Stabilization With PCSK9 Inhibitors., PMID:40335216
Cost-Effectiveness Analysis of Evolocumab or Inclisiran in Combination with Statins Versus Statin Monotherapy Among Patients with ASCVD in China., PMID:40323561
Hypercholesterolemia and cardiovascular disease: the dilemma of effective treatment for target achievement according to guidelines and national healthcare policies and a call to action., PMID:40322779
LDL-C Reduction with Evolocumab Among Patients with ASCVD in China: Real-World Evidence from Tianjin Metropolitan Area., PMID:40279014
Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial., PMID:40255182
Inadequate Response to PCSK9 Inhibitors., PMID:40250948
Consumption and expenditure of drugs used for the treatment of hypercholesterolemia: a governance analysis., PMID:40222896
Effect of PCSK9 inhibitor usage on coronary endothelial dysfunction in patients with hypercholesterolemia after coronary stenting: The CuVIC-2 trial., PMID:40221085
Safety and effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition: an updated review., PMID:40202526
Effects of Evolocumab on Coronary Plaque Composition and Microcalcification Activity by Coronary PET and CT Angiography., PMID:40178463
Effects of residual inflammatory and cholesterol risks on cardiovascular events with evolocumab in patients with acute coronary syndrome undergoing percutaneous coronary intervention., PMID:40165297
Importance of Genotype-Phenotype Correlation in the Population Screening of Familial Hypercholesterolemia., PMID:40125198
Body Mass Index, Comorbidities, and Ambulatory Care Visits: The REGARDS Study., PMID:40118809
Rethinking Cardiovascular Prevention: Cost-Effective Cholesterol Lowering for Statin-Intolerant Patients in Australia and the UK., PMID:40112156
Serum Lipids, Inflammation, and the Risk of Atrial Fibrillation: Pathophysiological Links and Clinical Evidence., PMID:40095683
Lower body mass index is associated with the achievement of target LDL in patients using PCSK9 inhibitors in Taiwan., PMID:40089775
Evolocumab ameliorates myocardial fibrosis and improves metabolic syndrome-induced cardiac dysfunction in rats via inhibiting PCSK9/NLRP3 inflammasome and Caspase-1 / IL-1β pathways., PMID:40064223
Effects of Inclisiran, Alirocumab, Evolocumab, and Evinacumab on Lipids: A Network Meta-Analysis., PMID:40026525
Dramatic response to Evinacumab in a North Indian girl with homozygous familial hypercholesterolemia., PMID:40022592
Achieved levels of apolipoprotein B and plaque composition after acute coronary syndromes: Insights from HUYGENS., PMID:40020597
Patient with Vulnerable Coronary Plaque and Treatment with Evolocumab: A Clinical Case., PMID:40004789
Treatment with PCSK9 inhibitors influences microRNAs expression and changes of arterial wall properties: a randomized controlled trial., PMID:40001082
Administration of Evolocumab in Patients with STEMI After Emergency PCI: A Real-World Cohort Study., PMID:39992584
Evolocumab Reduces Oxidative Stress and Lipid Peroxidation in Obese Zucker Rats., PMID:39982361
In vitro Stability Study of a Panel of Commercial Antibodies at Physiological pH and Temperature as a Guide to Screen Biologic Candidate Molecules for the Potential Risk of In vivo Asparagine Deamidation and Activity Loss., PMID:39979532
Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis., PMID:39975967
Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?, PMID:39947256
PCSK9 Expression in Vascular Smooth Muscle Cells: Role of Insulin Resistance and High Glucose., PMID:39940773
Popliteal Artery Rupture: A Rare but Life-Threatening Complication of Total Knee Arthroplasty., PMID:39935650
Resistance to conventional drug therapy and good response to lomitapide allowed the identification of a novel bi-allelic semi-dominant monogenic HoFH: a case report., PMID:39931866
Evolocumab attenuates myocardial ischemia/reperfusion injury by blocking PCSK9/LIAS-mediated cuproptosis of cardiomyocytes., PMID:39930254
Evolocumab induced short-term biliary stent blockage and acute cholangitis in a jaundice patient with pancreatic carcinoma: a rare complication of PCSK9 inhibitor., PMID:39925901
For research use only. Not for human or drug use.
